DE60318310T2 - Injizierbare arzneimittel die ein anthracendionderivat, mit antitumoraktivität, enthalten - Google Patents
Injizierbare arzneimittel die ein anthracendionderivat, mit antitumoraktivität, enthalten Download PDFInfo
- Publication number
- DE60318310T2 DE60318310T2 DE60318310T DE60318310T DE60318310T2 DE 60318310 T2 DE60318310 T2 DE 60318310T2 DE 60318310 T DE60318310 T DE 60318310T DE 60318310 T DE60318310 T DE 60318310T DE 60318310 T2 DE60318310 T2 DE 60318310T2
- Authority
- DE
- Germany
- Prior art keywords
- compositions
- hours
- amino
- isoquinoline
- aminoethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000259 anti-tumor effect Effects 0.000 title description 2
- 239000003814 drug Substances 0.000 title description 2
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 title 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 38
- SVAGFBGXEWPNJC-SPIKMXEPSA-N 6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN SVAGFBGXEWPNJC-SPIKMXEPSA-N 0.000 claims abstract description 32
- 239000011780 sodium chloride Substances 0.000 claims abstract description 19
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 14
- 239000008101 lactose Substances 0.000 claims abstract description 13
- 229920002307 Dextran Polymers 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 20
- 238000004108 freeze drying Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 6
- 239000008176 lyophilized powder Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 229950010678 pixantrone dimaleate Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 229920003079 Povidone K 17 Polymers 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011123 type I (borosilicate glass) Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002MI001040A ITMI20021040A1 (it) | 2002-05-16 | 2002-05-16 | Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale |
| ITMI20021040 | 2002-05-16 | ||
| PCT/EP2003/004871 WO2003097101A1 (en) | 2002-05-16 | 2003-05-09 | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60318310D1 DE60318310D1 (de) | 2008-02-07 |
| DE60318310T2 true DE60318310T2 (de) | 2008-12-11 |
Family
ID=11449903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60318310T Expired - Lifetime DE60318310T2 (de) | 2002-05-16 | 2003-05-09 | Injizierbare arzneimittel die ein anthracendionderivat, mit antitumoraktivität, enthalten |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20060199831A1 (https=) |
| EP (1) | EP1503797B1 (https=) |
| JP (1) | JP4624780B2 (https=) |
| AT (1) | ATE381944T1 (https=) |
| AU (1) | AU2003240613A1 (https=) |
| CA (1) | CA2486001C (https=) |
| DE (1) | DE60318310T2 (https=) |
| ES (1) | ES2298521T3 (https=) |
| FR (1) | FR12C0064I2 (https=) |
| IT (1) | ITMI20021040A1 (https=) |
| MX (1) | MXPA04011348A (https=) |
| WO (1) | WO2003097101A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2106788A1 (en) * | 2008-04-04 | 2009-10-07 | Ipsen Pharma | Liquid and freeze dried formulations |
| CN108113967A (zh) * | 2016-03-26 | 2018-06-05 | 夏建明 | 一种治疗非霍奇金淋巴瘤的冻干组合物及其制备方法 |
| CN105769757B (zh) * | 2016-03-26 | 2018-05-25 | 青岛市肿瘤医院 | 一种治疗非霍奇金淋巴瘤的注射液及其制备方法 |
| CN105997896B (zh) * | 2016-05-28 | 2019-07-05 | 长沙秋点兵信息科技有限公司 | 治疗非霍奇金淋巴瘤的注射用冻干粉及其制备方法 |
| CN106176630B (zh) * | 2016-08-03 | 2019-01-04 | 湖北丽益医药科技有限公司 | 一种注射用马来酸匹杉琼无菌粉末的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3590124A (en) * | 1967-06-27 | 1971-06-29 | Us Navy | Blood transfusion fluids having reduced turbulent friction properties |
| JP2690009B2 (ja) * | 1986-07-10 | 1997-12-10 | エーザイ 株式会社 | セフアロスポリン注射剤 |
| NZ241868A (en) | 1991-03-08 | 1995-05-26 | Univ Vermont | 6,9-bis(substituted-amino)benzo[g]isoquinoline-5,10-diones, preparation and pharmaceutical compositions thereof |
| JP3501471B2 (ja) * | 1992-06-15 | 2004-03-02 | 旭化成ファーマ株式会社 | カルシトニン類の安定化組成物および安定化法 |
| JPH08126685A (ja) * | 1994-01-26 | 1996-05-21 | Shionogi & Co Ltd | デキストラン類の凍結乾燥方法 |
| US5587382A (en) * | 1994-03-28 | 1996-12-24 | Boehringer Mannheim Italia, Spa | 6,9-bis[(2-aminoethyl) amino]benzo [g]isoquinoline-5,10- dione dimaleate; an aza-anthracenedione with reduced cardiotoxicity |
| PT1030839E (pt) * | 1997-11-10 | 2004-05-31 | Searle & Co | Utilizacao de iminoacucares para tratar a resistencia a multifarmacos |
| GB9808922D0 (en) * | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| IT1315253B1 (it) * | 1999-10-22 | 2003-02-03 | Novuspharma Spa | Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato |
-
2002
- 2002-05-16 IT IT2002MI001040A patent/ITMI20021040A1/it unknown
-
2003
- 2003-05-09 WO PCT/EP2003/004871 patent/WO2003097101A1/en not_active Ceased
- 2003-05-09 ES ES03729997T patent/ES2298521T3/es not_active Expired - Lifetime
- 2003-05-09 JP JP2004505097A patent/JP4624780B2/ja not_active Expired - Lifetime
- 2003-05-09 US US10/514,301 patent/US20060199831A1/en not_active Abandoned
- 2003-05-09 EP EP03729997A patent/EP1503797B1/en not_active Expired - Lifetime
- 2003-05-09 AT AT03729997T patent/ATE381944T1/de not_active IP Right Cessation
- 2003-05-09 DE DE60318310T patent/DE60318310T2/de not_active Expired - Lifetime
- 2003-05-09 CA CA2486001A patent/CA2486001C/en not_active Expired - Lifetime
- 2003-05-09 MX MXPA04011348A patent/MXPA04011348A/es active IP Right Grant
- 2003-05-09 AU AU2003240613A patent/AU2003240613A1/en not_active Abandoned
-
2010
- 2010-12-10 US US12/964,861 patent/US9211262B2/en not_active Expired - Lifetime
-
2012
- 2012-10-25 FR FR12C0064C patent/FR12C0064I2/fr active Active
-
2015
- 2015-11-10 US US14/937,689 patent/US20160256557A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20110144147A1 (en) | 2011-06-16 |
| CA2486001A1 (en) | 2003-11-27 |
| EP1503797B1 (en) | 2007-12-26 |
| FR12C0064I2 (fr) | 2013-08-16 |
| MXPA04011348A (es) | 2005-08-15 |
| US9211262B2 (en) | 2015-12-15 |
| ITMI20021040A0 (it) | 2002-05-16 |
| FR12C0064I1 (https=) | 2012-12-14 |
| ES2298521T3 (es) | 2008-05-16 |
| AU2003240613A1 (en) | 2003-12-02 |
| CA2486001C (en) | 2010-04-13 |
| US20060199831A1 (en) | 2006-09-07 |
| ITMI20021040A1 (it) | 2003-11-17 |
| JP4624780B2 (ja) | 2011-02-02 |
| US20160256557A1 (en) | 2016-09-08 |
| DE60318310D1 (de) | 2008-02-07 |
| ATE381944T1 (de) | 2008-01-15 |
| JP2005530792A (ja) | 2005-10-13 |
| WO2003097101A1 (en) | 2003-11-27 |
| EP1503797A1 (en) | 2005-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60033437T2 (de) | Glp-2 enthaltende formulierungen | |
| DE3536896C2 (de) | Lyophilisiertes, ein Anthracyclinglycosid enthaltendes pharmazeutisches Präparat und Verfahren zur Herstellung einer sterilen injizierbaren Lösung hieraus | |
| DE60132108T2 (de) | Gefriergetrocknetes pantoprazol-präparat und pantoprazol-injektion | |
| EP1687031B1 (de) | Pharmazeutische zubereitung enthaltend einen antikörper gegen den rezeptor für einen epidermalen wachstumsfaktor (egf-rezeptor) | |
| DE69228105T2 (de) | Verbesserte, gefriergetrocknete Ifosfamid-Zusammensetzungen | |
| DE69508837T2 (de) | Protein enthaltende stabilisierte Formulierung und Dosierungskit | |
| EP1455824B1 (de) | Lyophilisierte zubereitung enthaltend antikörper gegen den egf-rezeptor | |
| EP2865391B1 (de) | Verfahren zur Herstellung einer gefriergetrockneten pharmazeutischen Zusammensetzung mit Gehalt an Mitomycin C | |
| DE3031710C2 (de) | Salze von (+)-catechin, deren herstellung und verwendung sowie diese salze enthaltende pharmazeutische zubereitungen. | |
| WO1994014465A1 (de) | Stabile lyophilisierte pharmazeutische zubereitungen von g-csf | |
| DE3729863A1 (de) | Stabilisierte erythropoietin-lyophilisate | |
| DE69230672T2 (de) | Gonadotropin, das pharmazeutische zusammensetzungen mit sucrose stabilisator enthält | |
| DD298053A5 (de) | Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides | |
| DE60005376T2 (de) | Oxaliplatinhaltige parenteral anzuwendende stabilisierte arzneizubereitung und verfahren zu deren herstellung | |
| DE3333024A1 (de) | Neue pharmakologische zusammensetzungen auf basis von cis-platin und verfahren zu deren herstellung | |
| DE69420872T2 (de) | Hgh enthaltende pharmazeutische zubereitungen | |
| DE112012003995T5 (de) | Caspofunginpräparat mit geringem Verunreinigungsgehalt, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE2323187C2 (de) | Verfahren zur Herstellung einer stabilisierten, pulverförmigen Secretinzubereitung | |
| DE69928500T2 (de) | Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium-[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetat | |
| DE112012003996T5 (de) | Caspofunginpräparat mit geringem Verunreinigungsgehalt, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE60017444T2 (de) | Pharmazeutische formulierungen auf basis fester dispersionen | |
| DE60318310T2 (de) | Injizierbare arzneimittel die ein anthracendionderivat, mit antitumoraktivität, enthalten | |
| DE3628468A1 (de) | Neue applikationsformen fuer (alpha)-interferone | |
| DE69101784T2 (de) | Stabilisierte zusammensetzung enthaltend ein fibroblastwachstumsfaktor. | |
| DE2608079A1 (de) | Arzneipraeparat in form eines trockenpraeparats zur herstellung von injektionen |